Showing 1 - 4 results of 4 for search 'Eva Schrezenmeier', query time: 0.01s Refine Results
  1. 1
    Phosphatidylcholine-specific B cells are enriched among atypical CD11chigh and CD21low memory B cells in antiphospholipid syndrome

    Phosphatidylcholine-specific B cells are enriched among atypical CD11chigh and CD21low memory B cells in antiphospholipid syndrome by Eduard Nitschke, Eduard Nitschke, Van Duc Dang, Van Duc Dang, Van Duc Dang, Hector Rincon-Arevalo, Hector Rincon-Arevalo, Hector Rincon-Arevalo, Hector Rincon-Arevalo, Franziska Szelinski, Franziska Szelinski, Jacob Ritter, Jacob Ritter, Eva Schrezenmeier, Eva Schrezenmeier, Eva Schrezenmeier, Eva Schrezenmeier, Tobias Alexander, Tobias Alexander, Tuan Anh Le, Tuan Anh Le, Yidan Chen, Yidan Chen, Annika Wiedemann, Annika Wiedemann, Jose-Bernardino Gonzalez, Jose-Bernardino Gonzalez, Andreia C. Lino, Ana-Luisa Stefanski, Ana-Luisa Stefanski, Thomas Dörner, Thomas Dörner

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Clinical outcomes in kidney transplant recipients receiving tixagevimab/cilgavimab for outpatient treatment of COVID-19: a single-center retrospective study

    Clinical outcomes in kidney transplant recipients receiving tixagevimab/cilgavimab for outpatient treatment of COVID-19: a single-center retrospective study by Bilgin Osmanodja, Friederike Bachmann, Mira Choi, Wiebke Duettmann, Georgios Eleftheriadis, Fabian Halleck, Marcel G. Naik, Eva Schrezenmeier, Bianca Zukunft, Klemens Budde

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    The SmartNTx-study: a prospective, randomized controlled trial to investigate additional interventional telemedical management versus standard aftercare in kidney transplant recipients

    The SmartNTx-study: a prospective, randomized controlled trial to investigate additional interventional telemedical management versus standard aftercare in kidney transplant recipi... by Mario Schiffer, Lars Pape, Julia K. Wolff, Julia K. Wolff, Raoul Gertges, Vanessa Visconti, Karen Reichert, Anja Pfau, Anne Dieterle, Katja Sauerstein, Andreas Kribben, Kristina Boss, Sinem Karaterzi, Felix Nensa, Philipp Winneckens, Mario Cypko, Mario Cypko, Wiebke Duettmann, Bianca Zukunft, Eva Schrezenmeier, Marcel G. Naik, Fabian Halleck, Roland Roller, Sebastian Möller, Sebastian Möller, Oliver Amft, Oliver Amft, Klemens Budde

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialResearch in context

    Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialResearch in context by Simone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, Fabian Halleck, Antoine Durrbach, Lynn Peters, Anna-Teresa Tremmel, Alina Seidel, Marita Führer, Friederike Bachmann, Jens Schrezenmeier, Jochen Greiner, Sixten Körper, Henrike Hofmann, Carolin Ludwig, Christiane Vieweg, Bernd Jahrsdörfer, Klemens Budde, Michael Schmidt, Jan Münch, Nizar Joher, Etienne Daguindau, Beate Grüner, Gaëlle Brunotte, Charline Vauchy, Erhard Seifried, Daniel Bradshaw, Lise J. Estcourt, David J. Roberts, Eric Toussirot, Bart Rijnders, Pierre Tiberghien, Hubert Schrezenmeier

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: